^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PD-407824

    i
    Other names: PD-407824
    Company:
    Weill Cornell Medical College
    Drug class:
    Chk1 inhibitor
    Related drugs:
    2years
    Integrative analysis of m3C associated genes reveals METTL2A as a potential oncogene in breast Cancer. (PubMed, J Transl Med)
    Through drug sensitivity analysis, Trifluridine, PD407824, and Taselisib were shown to be effective drugs for METTL2A-positive BRCA patients. Overall, our research conducts a holistic view of the expression level and prognostic signature of m3C-related genes with multiple malignancies. Importantly, METTL2A has been intensely explored as a potential oncogene in BRCA, to aid the development of potential drug agents for precision therapy in breast cancer patients.
    Journal • BRCA Biomarker
    |
    BRCA (Breast cancer early onset) • METTL2A (Methyltransferase 2A)
    |
    taselisib (GDC-0032) • PD-407824